| |
HBV Meeting Paris: Next-generation core inhibitors demonstrate increased potency and distinct biochemical properties compared to first-generation core inhibitors
|
| |
| |
2022 International HBV meeting, September 18–22, 2022
Nuruddin Unchwaniwala1, Steven P Dunkelbarger2, Adam Zlotnick2,3, Karolyn Pionek4, Daniel D Loeb4, William Delaney1, Kathryn M Kitrinos1
1Assembly Biosciences, Inc., South San Francisco, CA, USA; 2Door Pharmaceuticals, LLC., Bloomington, IN, USA; 3Indiana University, Bloomington, IN, USA; 4University of Wisconsin-Madison, Madison, WI, USA
|
|
| |
| |
|
|
|
